Dose Ranging Study of Albiglutide in Japanese Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 215 participants.

Also called NCT01098461

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 215 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01098461
Other papers using this trial's data
  • A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus Current medical research and opinion, 2014-06 DOI, PubMed 24552155

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01098461. Randomized; double masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2014-07-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose Ranging Study of Albiglutide in Japanese Subjects
Condition
Diabetes Mellitus, Type 2
Intervention (Biological)
albiglutide
Intervention (Biological)
placebo
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct01098461
Content hash
8cd4f6895f6927d297d3f95457ee9686a1ef9b6c9af453286ecdde6863c3c86b